欧洲杯投注入口维健医药将捏续罗致对患者、协作伙伴和职工的承诺-欧洲杯正规下单平台(官方)网站/网页版登录入口/手机版

2024年9月30日，香港维健医药集团（以下简称“维健医药”）发扬文告，已收效完成对日本协和麒麟（以下简称“协和麒麟”）株式会社全资子公司——协和麒麟（中国）制药有限公司（以下简称“协和麒麟中国”）股权收购的交割。

交割之后，维健医药将捏有协和麒麟中国100%股权，并获取协和麒麟在中国上市贸易化的五个原研品牌药品的长久贸易化及坐蓐权柄以及改日在肾科和血液科管线的优先贸易化权柄。此外，维健医药还与协和麒麟刚烈了寰球重磅产物麟平®和惠尔金®的贸易化许可公约，获取其在中国的耐久贸易化权柄。

这次交往，自2024年8月1日文告签约以来，历时两个月。在此期间内，表情得到了各方的高度嗜好与相沿，两边团队或者在短短61天的期间里，完成表情所涉交割范例和附属公约的签署，使得表情高效、成功、幽闲的交割，获利于两边高度专科化的表情团队，以及内、外部团队、协作伙伴多方的积极勤勉和高效协同。

维健医药董事长/首创东谈主兼CEO王威先生暗示：

咱们对股权收购的收效完成感到相称喜跃，它将显赫增强咱们在改进药物研发和贸易化规模的轮廓竞争力；意味着维健医药从一家医药贸易化扩充企业成为一家大型改进型生物制药企业的政策转型的成功完成；更是维健医药实在迈向维健2.0时期的要紧里程碑事件。改日，咱们将长久秉捏‘患者为先’的初心，悉力于于为寰球患者提供更多更好的颐养决议。此交割的圆满终止，维健医药将会经受和发扬协和麒麟中国的业务、捏续扩大中国市集，得志更多未被得志的患者需求。

维健医药集团履行董事、联席CEO郝景辉先生暗示：

从8月1日签约到今天的高效交割，历时不到两个月，这一成就离不开两边处理层和交往团队的专科互信、一点不苟与精诚协作。手脚耐久政策协作伙伴，维健医药与协和麒麟长久保捏着高超且邃密的协作关系，共同构建了基于互惠互信共赢原则的共生关系。今天的收效交割，象征着两边协作迈入了全新的发展阶段。改日，维健医药将捏续罗致对患者、协作伙伴和职工的承诺，联袂协和麒麟及繁密寰球优秀政策协作伙伴，将更多启程点的原研改进药品带给中国患者，共创愈加后光的改日。

跟着本次交割的圆满终止，维健医药与协和麒麟的协作发扬迈入了全新的发展阶段。这不仅是两边协作经过中的一个迫切里程碑，更是象征着两边在政策层面的深度会通。维健医药将以此为机会，全面而深切地整合协和麒麟中国在研发、坐蓐及贸易化规模的丰富资源。通过资源的优化建立与分享，维健医药将构建起更为专科、完善和高效的全链路贸易化体系，夯实公司的竞争上风，为公司的捏续发展和转型注入了苍劲的发展能源。

量度改日，维健医药将依托这些上风，阻挡追求超卓。公司将长久以患者为中心，悉力于于得志患者日益增长的健康需求，捏续膨胀咱们的自有和协作产物管线。通过阻挡的改进与打破，维健医药将和咱们的优秀产业链伙伴一齐共同始创医药产业的新篇章，为健康奇迹孝顺更多的灵巧与力量。

对于香港维健医药集团

香港维健医药集团是一家总部位于香港的启程点生物制药公司，在大中华地区开展贸易运营，并在亚洲和欧洲区域阻挡膨胀业务。公司专注于改进药物的贸易化，悉力于于为心肾疾病、血液肿瘤、胃肠疾病、呼吸和抗感染疾病和萧疏病以终点他未得志和严重未被得志的医疗需求患者提供打破性疗法。

维健医药与繁密世界启程点的制药和生物本领公司建立了收效的耐久协作伙伴关系，创造了一个私有而有兴味的多元化产物组合，包括15种以上的专科产物，遮蔽贸易和后期临床阶段。维健医药长久以患者为中心，信守对协作伙伴的承诺，阻挡膨胀其产物组合，寻求通过其寰球协作伙伴网罗引进更多的变革性疗法。

欲了解更多信息，请傍观www.winhealth.hk。

对于协和麒麟

协和麒麟悉力于于研发具有改造生命价值的改进型药物。手脚一家总部位于日本的寰球化特药公司，咱们在药物研发和生物本领改进等方面捏续参加卓绝70年，当今，咱们正悉力于于研发先进的抗体本领、细胞和基因疗法，以期匡助患有严重疾病或萧疏疾病的患者。咱们在寰球四个地区——日本、亚太、北好意思和EMEA（欧洲、中东和非洲），因共同的价值不雅，对可捏续发展的承诺以及悉力于于为东谈主们带来笑脸的服务而高超相联。如需了解更多信息，请傍观www.kyowakirin.com。

英文版

（凹凸滑动查抄更多）

]article_adlist-->

On September 30, 2024, Hong Kong Winhealth Pharma Group (hereinafter referred to as "Winhealth Pharma") officially announced the successful completion of the equity acquisition of Kyowa Kirin (China) Pharmaceutical Co., Ltd. (hereinafter referred to as "Kyowa Kirin China"), a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (hereinafter referred to as "Kyowa Kirin").

Following the closing, Winhealth Pharma will hold 100% equity of Kyowa Kirin China and obtain the permanent commercialization and production rights of five original brand drugs commercialized in China by Kyowa Kirin, as well as the priority commercialization rights of future pipeline products in the nephrology and hematology fields. Additionally, Winhealth Pharma has also signed a commercial license agreement with Kyowa Kirin for the global blockbuster products Crysvita® and Poteligeo®, securing their long-term commercialization rights in China.

This transaction has spanned two months since the signing was announced on August 1, 2024. During this period, the project has received high-level attention and support from all parties. The project teams of both sides were able to complete the closing procedures and the signing of ancillary agreements involved in the project in just 61 days. The efficient, smooth, and stable closing of the project is attributable to the highly professional project teams of both sides and the active efforts and efficient collaboration of internal and external teams and multiple partners.

Mr. Wang Wei, Chairman/Founder and CEO of Winhealth Pharma, said:“We are extremely delighted with the successful completion of the equity acquisition. It will significantly enhance our comprehensive competitiveness in the fields of innovative drug research and development and commercialization. It means the smooth completion of Winhealth Pharma's strategic transformation from a pharmaceutical commercial promotion enterprise to a large innovative biopharmaceutical enterprise. It is also a significant milestone event as Winhealth Pharma truly steps into the Winhealth 2.0 era. In the future, we will always adhere to the original intention of ‘patient comes first’ and be committed to providing more and better treatment options for patients around the world. With the successful conclusion of this transaction, Winhealth Pharma will inherit and carry forward the business of Kyowa Kirin China, continuously expand the Chinese market, and meet more unmet patient needs.”

Mr. Hao Jinghui, Executive Director and Co-CEO of Winhealth Pharma, remarked, “From the signing on August 1 to today's efficient closing, it took less than two months. This achievement is inseparable from the professional mutual trust, meticulousness, and sincere cooperation of the management and transaction teams of both sides. As a long-term strategic partner, Winhealth Pharma and Kyowa Kirin have always maintained a close and excellent cooperative relationship and jointly established a symbiotic relationship based on the principles of mutual benefit, mutual trust, and win-win. Today's successful closing signals that the cooperation between the two sides has entered a new stage of development. In the future, Winhealth Pharma will continue to uphold its commitments to patients, partners, and employees. Together with Kyowa Kirin and many outstanding global strategic partners, we will bring more leading original innovative drugs to Chinese patients and create a more glorious future."

With the successful closing of this transaction, the cooperation between Winhealth Pharma and Kyowa Kirin has officially entered a new stage of development. This is not only an important milestone in the cooperation process between the two sides but also indicates the deep integration of the two sides at the strategic level. Winhealth Pharma will seize this opportunity to comprehensively and deeply integrate the abundant resources of Kyowa Kirin China in the fields of research and development, production, and commercialization. Through the optimized allocation and sharing of resources, Winhealth Pharma will establish a more professional, complete, and efficient full-link commercialization system, consolidate the company's competitive advantages, and inject strong impetus for the company's continuous development and transformation.

Looking ahead, Winhealth Pharma will rely on these advantages and continuously pursue excellence. The company will always center on patients, be committed to meeting the growing health needs of patients, and continuously expand our own and cooperative product pipelines. Through continuous innovation and breakthroughs, Winhealth Pharma will work together with our excellent industrial chain partners to jointly create a new chapter in the pharmaceutical industry and contribute more wisdom and strength to the health cause.

About Hong Kong Winhealth Pharma Group

Hong Kong Winhealth Pharma Group is a leading biopharmaceutical company based in Hong Kong, with commercial operations across the Greater China Area and an expanding regional footprint in Asia and Europe. Specializing in the commercialization of innovative medicines, the company is dedicated to delivering breakthrough therapies for patients with cardio-renal, gastrointestinal, respiratory and anti-infectious and rare diseases, as well as other unmet and severely underserved medical needs.

WinHealth has established successful long-term partnerships with numerous world-leading pharmaceutical and biotechnology companies, creating a uniquely impactful and diversified portfolio that includes over 15 specialty products in both commercial and late clinical stages. Committed to patients and partners, WinHealth continuously expands its portfolio and seeks to bring more transformative therapies from its global network of partners.

About Kyowa Kirin

Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by a severe or rare disease. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.